Company Description
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.
The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb.
Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
| Country | United States |
| Founded | 2015 |
| IPO Date | Sep 20, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 275 |
| CEO | Krish Krishnan |
Contact Details
Address: 2100 Wharton Street, Suite 701 Pittsburgh, Pennsylvania 15203 United States | |
| Phone | 412 586 5830 |
| Website | krystalbio.com |
Stock Details
| Ticker Symbol | KRYS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001711279 |
| CUSIP Number | 501147102 |
| ISIN Number | US5011471027 |
| Employer ID | 82-1080209 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Krish S. Krishnan M.B.A., M.S. | Founder, Chairman, President and Chief Executive Officer |
| Suma M. Krishnan | Founder, President of Research & Development and Director |
| Kathryn A. Romano CPA | Executive Vice President and Chief Accounting Officer |
| John Thomas | General Counsel and Corporate Secretary |
| John Karakkal | Vice President of North American Sales and Marketing |
| Christine Wilson | Head of U.S. Sales and Marketing |
| Dr. Stephane Paquette Ph.D. | Vice President of Corporate Development |
| Josh Suskin | Senior Director and Head of US Human Resources |
| Laurent Goux | Senior Vice President and GM of Europe |
| David Chien | Senior Vice President of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 2, 2025 | 8-K | Current Report |
| May 19, 2025 | 8-K | Current Report |
| May 13, 2025 | 8-K | Current Report |
| May 6, 2025 | 8-K | Current Report |
| May 6, 2025 | 10-Q | Quarterly Report |
| May 6, 2025 | 8-K | Current Report |
| Apr 28, 2025 | 8-K | Current Report |
| Apr 3, 2025 | ARS | Filing |
| Apr 3, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 3, 2025 | DEF 14A | Other definitive proxy statements |